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Background and Objective: Agranulocytosis is a rare and potentially life-threatening
complication of metamizole (dipyrone) intake that is characterized by a loss of circulating
neutrophil granulocytes. While the mechanism underlying this adverse drug reaction
is not well understood, involvement of the immune system has been suggested. In
addition, associations between genetic variants in the Human Leukocyte Antigen (HLA)
region and agranulocytosis induced by other drugs have been reported. The aim of
the present study was to assess whether genetic variants in classical HLA genes are
associated with the susceptibility to metamizole-induced agranulocytosis (MIA) in a
European population by targeted resequencing of eight HLA genes.
Design: A case-control cohort of Swiss patients with a history of neutropenia or
agranulocytosis associated with metamizole exposure (n = 53), metamizole-tolerant
(n = 39) and unexposed controls (n = 161) was recruited for this study. A high-throughput
resequencing (HTS) and high-resolution typing method was used to sequence and
analyze eight HLA loci in a discovery subset of this cohort (n = 31 cases, n = 38 controls).
Identified candidate alleles were investigated in the full Swiss cohort as well as in two
independent cohorts from Germany and Spain using HLA imputation from genome-
wide SNP array data. In addition, variant calling based on HTS data was performed in
the discovery subset for the class I genes HLA-A, -B, and -C using the HLA-specific
mapper hla-mapper.
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Results: Eight candidate alleles (p < 0.05) were identified in the discovery subset,
of which HLA-C∗04:01 was associated with MIA in the full Swiss cohort (p < 0.01)
restricted to agranulocytosis (ANC < 0.5 × 109/L) cases. However, no candidate allele
showed a consistent association in the Swiss, German and Spanish cohorts. Analysis
of individual sequence variants in class I genes produced consistent results with HLA
typing but did not reveal additional small nucleotide variants associated with MIA.
Conclusion: Our results do not support an HLA-restricted T cell-mediated immune
mechanism for MIA. However, we established an efficient high-resolution (three-
field) eight-locus HTS HLA resequencing method to interrogate the HLA region and
demonstrated the feasibility of its application to pharmacogenetic studies.
Keywords: drug-induced agranulocytosis, metamizole (dipyrone), HLA, pharmacogenetics, high-throughput
sequencing, next generation sequencing, genetic association studies
INTRODUCTION
Metamizole (dipyrone) is a non-opioid pro-drug with analgesic
and antipyretic properties that has been used in clinical practice
since the early 1930s (Hinz et al., 2016). Despite an overall
good efficacy and low gastrointestinal toxicity compared to other
medications (Arellano and Sacristán, 1990; Andrade et al., 1998;
Sánchez et al., 2002; Blaser et al., 2015), exposure to this drug
has been associated with the risk of agranulocytosis, a rare
and potentially fatal blood dyscrasia characterized by a decrease
in circulating neutrophil granulocytes (Blaser et al., 2017).
Previous studies have reported widely varying risk estimates
for metamizole-induced agranulocytosis (MIA) such as 1:1500
prescriptions in Sweden and 1:1’000’000 inhabitants and year
in Spain (Hedenmalm and Spigset, 2002; Ibáñez et al., 2005).
Currently, national regulations worldwide differ concerning
metamizole use (Van der Klauw et al., 1999; Ibáñez et al., 2005;
Basak et al., 2010) with market withdrawal in countries such as
the United States, the United Kingdom, Denmark, and Sweden,
whereas it remains a frequently used prescription drug in other
countries like Germany and Switzerland, or even readily available
over-the-counter in countries like China, Mexico, and Brazil
(Chan and Chan, 1996; Hedenmalm and Spigset, 2002; Blaser
et al., 2015; Stammschulte et al., 2015; Miljkovic et al., 2018).
The underlying mechanisms by which metamizole induces
agranulocytosis have not yet been fully elucidated. Similarly,
risk factors that may render some patients more susceptible
to this adverse drug reaction are poorly understood and there
are no effective strategies to prevent the occurrence of MIA.
Previous studies have suggested that the mechanism of toxicity
may involve an immunological component, including T-cell
mediated elimination of neutrophils (Claas, 1996; Uetrecht,
1996; García-Martínez et al., 2003; Andres et al., 2009). Given
their role in cell-mediated innate and adaptive immunity, an
association of specific human leukocyte antigen (HLA alleles),
as indicated by a small previous study (Vlahov et al., 1996),
may provide evidence of such an immune-mediated mechanism.
Indeed, agranulocytosis induced by several other drugs such
as thiamazole (methimazole), clozapine and sulfasalazine has
recently been found to be associated with specific HLA alleles
such as HLA-B∗27:05, HLA-B∗08:01, HLA-A∗31:01 and HLA-
DQB1 alleles, respectively (Hallberg et al., 2016; Legge et al.,
2017; Wadelius et al., 2018). Furthermore, the frequencies of HLA
alleles can vary between populations and consequently so could
the susceptibility to associated adverse drug reactions (Lucena
et al., 2011). A recent commentary suggested the possibility
of an increased susceptibility to MIA in the British, Irish and
Scandinavians compared to other populations, which could be
mediated by specific HLA alleles with a higher frequency in
these populations (Shah, 2018). So far, larger studies investigating
possible associations between genetic variation in the HLA
region and MIA are lacking and are sorely needed to improve
our knowledge of the mechanism underlying the hematological
complications of pharmacotherapy with metamizole and to
attempt to minimize the risk of MIA in the near future.
The human leukocyte antigen (HLA) region stands out from
the rest of the human genome by virtue of its exceptional level
of polymorphism and high gene density (Shiina et al., 2009;
Robinson et al., 2015). A wealth of associations between the HLA
region and adverse drug reactions (ADRs) have been reported,
yet the identification of underlying causal variants has been
handicapped by the strong linkage disequilibrium (LD) in this
region (Shiina et al., 2009; McCormack et al., 2011; Alfirevic
et al., 2012; Hosomichi et al., 2013). With the advent of high-
throughput sequencing (HTS), it is now possible to profile HLA
alleles at unprecedented resolution and reduced ambiguity and
analyze full-length genes including intronic regions, potentially
enabling deeper insights into the etiopathogenesis of HLA-ADR
associations (Kishore and Petrek, 2018).
While several commercial HTS-based HLA typing kits are
available, their cost may be prohibitive for population-based
studies in a research context. Alternatively, non-commercial
primers to amplify full-length HLA genes have been described
(Shiina et al., 2012; Hosomichi et al., 2013; Ehrenberg et al.,
2017), as well as several freely available bioinformatics software
tools to achieve HLA typing from HTS reads (Warren et al.,
2012; Bai et al., 2014; Nariai et al., 2015; Kawaguchi et al., 2017;
Lee and Kingsford, 2018). Previously published non-commercial
HLA HTS methods (Hosomichi et al., 2013; Ehrenberg et al.,
2017) used the tagmentation approach during sequencing library
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preparation, which may lead to a biased pattern of coverage, such
as an underrepresentation of GC-rich segments in introns 2 and 3
ofHLA-A (Lima et al., 2019). Potentially, this bias may be reduced
with alternative fragmentation approaches.
Overall, while the literature is highly enthusiastic about HTS-
based HLA typing (Carapito et al., 2016; Kishore and Petrek,
2018), less attention has been brought to novel challenges that
go hand in hand with these new methods. The vast degree of
polymorphism of HLA genes has spawned new bioinformatics
challenges associated with profiling HLA HTS data, such as
identifying the best match of sequence reads to highly similar
reference sequences (e.g., different alleles of the same gene as well
as conserved regions between genes) and the lack of reference
sequences encompassing the full genomic sequence for many
alleles, which have recently been summarized (Klasberg et al.,
2019). In this study, we assessed the feasibility of high-throughput
sequencing of eight full-length classical HLA genes using non-
commercial primers and evaluated freely available bioinformatics
tools to study classical HLA genes at the level of individual
alleles as well as individual small nucleotide variants (SNVs) to
investigate potential associations between variation in these genes
and metamizole-induced agranulocytosis.
MATERIALS AND METHODS
Participants and Setting
Patients for this retrospective observational case-control study
were recruited at two Swiss University Hospital (Basel and
the Inselspital Bern University Hospital). Patients diagnosed
with new-onset neutropenia or agranulocytosis while under
metamizole therapy between 2005 and 2017, metamizole-
tolerant control patients, as well as healthy population controls
were included. Collection of biological materials and clinical
information was undertaken with a written informed consent
and following the principles of good clinical practice according
to the Declaration of Helsinki. This study was approved by
the local ethics committees (“Ethikkommission Nordwest- und
Zentralschweiz” and “Kantonale Ethikkommission Bern,” BASEC
protocol number 2015–00231). Clinical data was collected as
described previously (Rudin et al., 2019c).
Cases were restricted to ≥18 years of age and development
of neutropenia (absolute neutrophil count < 1.5 × 109/L)
within at least 1 day after the first intake or at the latest
2 weeks after discontinuing metamizole. Neutrophil counts
prior to metamizole intake were not available for the majority
of cases. Metamizole-tolerant control patients had received
metamizole treatment with a daily dose of at least 500 mg for
at least 28 consecutive days without any reported drug-related
hematological complications. Population controls with no prior
exposure to metamizole were recruited via advertisement in
regional print or online media.
Out of the total of 45 cases having met the abovementioned
inclusion criteria, a discovery subset of 31 metamizole-induced
agranulocytosis/neutropenia (MIA/MIN) patients was selected
for HTS analysis based on clinical factors supporting metamizole
as the most likely causing agent. Selection was not based on
the absolute neutrophil count (ANC) but on the lowest number
of potentially confounding factors such as comorbidities (i.e.,
ongoing infectious diseases such as HIV), chemotherapy, and
immunosuppressive therapy with cytotoxic drugs that may have
contributed to agranulocytosis or neutropenia (Hallberg et al.,
2016). Due to limits of sequencing library multiplexing, two
of the originally selected cases could not be included for HTS
analysis. In addition, the HTS discovery subset included all
metamizole-tolerant individuals of European ancestry (n = 38).
This discovery subset was used to obtain high-resolution HLA
typing for a cost-effective discovery of potential candidate alleles
associated with MIA/MIN.
For follow-up of candidate alleles, HLA imputation data from
the full Swiss cohort, including the 14 cases not selected for
HTS analysis and 153 population controls was used, as well
as data from 286 independent subjects recruited in Germany
(12 cases and 96 controls) and Spain (31 cases and 147
controls) by investigators from the European Drug-induced
Agranulocytosis Consortium (EuDAC) as described previously
(Hallberg et al., 2016).
DNA and Template Preparation
Genomic DNA from whole blood or buffy coat was extracted
and purified using the QIAamp DNA Blood Maxi and Midi
Kits (Qiagen) according to the manufacturer’s instructions.
DNA samples from subjects of the discovery cohort were
amplified at eight loci (HLA-A, -B, -C, -DRB1, -DQA1,
-DQB1, -DPA1 and -DPB1) by full gene-length long-range
PCR (Polymerase Chain Reaction). Novel primers for HLA-
DQA1, -DPA1 (reverse primer), and -DPB1 (reverse primer) were
designed in-house, while a combination of previously described
locus-specific primers (Shiina et al., 2012; Hosomichi et al.,
2013; Ehrenberg et al., 2017) was used to amplify the other five
genes (Supplementary Table S1). Each locus was amplified in
25 µL reaction volumes consisting of 50–250 ng of gDNA, 1x
PrimeSTAR GXL Buffer, 0.625 U PrimeSTAR GXL Polymerase
(Takara Bio Inc), 0.2 µM dNTPs and 0.08 mM of the respective
forward and reverse primer mix using the PCR cycling conditions
described in Supplementary Table S2. To confirm amplification,
2 µL of each PCR product were analyzed on 0.8% agarose
gels. The remaining product was purified by the QIAquick
PCR Purification Kit (Qiagen) and quantified with a Qubit 4
Fluorometric system (Life Technologies).
Multiplex Library Preparation and
Sequencing of the Discovery Subset
For library preparation with the QIAseq FX DNA Library Kit
(Qiagen), all eight HLA amplicons were pooled in equimolar
amounts (except for HLA-DRB1, where the total input amount
was doubled due to lower coverage observed in preliminary
experiments) in two amplicon pools according to their sizes (see
Supplementary Table S1) resulting in two libraries per subject.
Amplicon pools were enzymatically fragmented (3 min for the
shorter pool “S” and 4 min for the longer pool “L”), then subjected
to size-selection clean-up (GeneRead Size Selection Kit, Qiagen),
uniquely dual-indexed at the subject level, purified with magnetic
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beads (CleanNGS Kit, GC biotech) and the resulting libraries
of “S” and “L” amplicons of all subjects were pooled separately
in equimolar amounts. For sequencing, one part of pooled “S”
libraries (3 nM) and three parts (volume) of pooled “L” libraries
(3 nM) were combined and the final library was diluted to an
approximate concentration of 2 nM.
The final library pool was diluted in HT-1/5% Tris-HCL,
pH8.5 with 5% PhiX spiked in and sequenced on a MiSeq
instrument using the paired-end 500 cycle (2x 250bp paired-
end reads) MiSeq Reagent v2 Kit (both Illumina). Libraries for
two samples were sequenced as part of the protocol optimization
using a MiSeq Nano v2 (2× 250 bp paired-end reads) Kit.
The PCR amplification and library preparation protocol used
in this study was adapted based on preliminary experiments
using anonymized samples previously HLA typed by validated
SSP-PCR based methods (LinkSeq for HLA, Linkage Biosciences;
HLA-FluoGene ABC, Innotrain). Using this optimized protocol,
100% concordant results with SSP-PCR typing were obtained
for HLA-A, -B, -C, -DQA1, -DQB1, -DPA1, -DPB1 and 95%
concordant results in HLA-DRB1 in 10 investigated subjects (20
alleles total; data not shown).
Quality Control and HLA Typing of the
Discovery Subset
Quality of the obtained raw sequence reads was assessed using
FastQC v.0.11.71 and MultiQC v.1.5 (Ewels et al., 2016) and
trimmed as described in more detail in the Supplementary
Appendix using the BiomedicalWorkbench v.4.1.1 (QIAgen).
Briefly, trimming and read filtering consisted of removal of
Universal Illumina Adapters, removal of PCR primer sequences,
and removal of reads with length < 100 bp. For each individual,
paired reads from both sequencing libraries were combined for
subsequent analyses.
HLA typing of the trimmed and paired sequencing reads
was performed with both the freely available tool HLA-HD
v.1.2.0.1 (Kawaguchi et al., 2017) using read mapping with
Bowtie 2 (v.2.3.4.1) (Langmead and Salzberg, 2012) and the
IPD-IMGT/HLA reference dictionary v.3.34.0 (Robinson et al.,
2015), as well as with the commercial software NGSengine
v.2.8.0.9796 (GenDx, IPD-IMGT/HLA database v.3.30.0). Details
are provided in the Supplementary Appendix.
Typing results from HLA-HD and NGSengine were compared
at three-field resolution, with the exception of HLA-DRB1. If
typing results were discordant, allele frequency information
as reported in the Allele Frequency Net Database (González-
Galarza et al., 2015), as well as reported DRB1-DQB1 haplotype
frequencies (Maiers et al., 2007) were incorporated to infer the
more likely typing result. The plausibility of HLA-DRB1 typing
results was assessed based on the presence of related genes
and pseudogenes and information on known DRB haplotypes
(Kotsch and Blasczyk, 2000). Additional details on how the
comparisons were performed are provided in the Supplementary
Methods. Genotype frequencies of the accepted three-field
resolution HLA typing results were tested for deviations from
1https://www.bioinformatics.babraham.ac.uk/projects/fastqc/ (last accessed
04.12.2019)
Hardy-Weinberg equilibrium (HWE) using Fisher’s exact test
implemented in Genepop on the web v.4.2 (Raymond and
Rousset, 1995; Rousset, 2008). Depth of coverage was assessed
using the mean depth of coverage in exon 2 (or exon 3 in the
case of HLA-DRB2, which lacks exon 2) and refers to the sum of
the depth of coverage of the two alleles of the respective gene and
sample as reported by HLA-HD.
Genotyping Using Genome-Wide SNP
Arrays
Genome-wide genotyping was performed using the Infinium
CoreExome-24 V.1.2 BeadChip (Illumina) in the 253 Swiss
individuals recruited for the present study (53 cases, 39 tolerant,
and 161 unexposed controls). Thirty-one agranulocytosis cases
from Spain and 147 Spanish controls had previously been
genotyped with the Illumina HumanOmni 2.5M chip (Illumina),
while an additional 36 Spanish controls had been genotyped
with the Illumina HumanOmni1-Quad 1M chip. Cases (n = 12)
and controls (n = 96) from Germany had been genotyped
with the Illumina HumanOmniExpress 700K. Genotype calls
were generated with the GenomeStudio Software (Illumina) and
coordinates were based on the Genome Reference Consortium
GRCh37 (hg19) build.
Standard quality control (Turner et al., 2011; Guo et al., 2014;
Alonso et al., 2015) and data management was performed with
PLINK v.1.7 and v.1.9 (Purcell et al., 2007). Specifically, data was
filtered individually for each cohort (Swiss, Spanish, German)
on the basis of single nucleotide polymorphisms (SNP) genotype
call rates (>98%), sample genotype call rates (>98%), deviation
from HWE in controls (p < 0.001) and minor allele frequency
(MAF > 1%).
We performed multi-dimensional scaling (MDS) analysis
including the combined data from the Swiss and EuDAC cohorts
together with data from HapMap phase III samples to identify
nine and five ethnic outliers in the Swiss and the EuDAC
cohorts, respectively. Based on pairwise identity-by-descent
(IBD) estimation, we confirmed that three pairs of individuals
in the EuDAC cohorts were closely related. One individual from
each pair was randomly selected to be excluded from subsequent
analyses. MDS was also applied to variants in the HLA region
to investigate potential global genetic differences between the
cohorts in this region (see more detailed description in the
Supplementary Appendix).
Imputation of SNPs and HLA Types From
Genome-Wide SNP Array Data
SNP imputation was performed by minimac3 on the Michigan
Imputation Server (Das et al., 2016) using the Haplotype
Reference Consortium (HRC 1.1 2016) reference panel
(McCarthy et al., 2015) on the basis of pre-imputation SNP-level
validated data2 from each cohort (see Supplementary Table S3).
HLA types of the five genes with at least one identified
candidate allele (HLA-B, -C, -DQA1, -DQB1 and -DRB1)
were imputed using HIBAG (Zheng et al., 2014) with the
2https://www.well.ox.ac.uk/$\sim$wrayner/tools/
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published parameter estimates from the European reference
population based on hg19 (Zheng et al., 2014) in the three
independent cohorts. HLA imputation of the Swiss cohort was
performed using imputed SNPs with R2 ≥ 0.9 to increase the
number of SNPs used in the imputation model. Unimputed
SNPs were used to impute HLA types of the German and
Spanish cohorts, since a higher proportion of SNPs of the
imputation model were directly genotyped. HLA imputation
accuracy was estimated using the samples from the discovery
subset that had HLA typing results available from both
HTS and HLA imputation assuming results from HTS as
the correct typing.
Investigation of Individual Variants in
Classical HLA Class I Genes From HTS
Data in the Discovery Subset
Obtaining reliable variant calls in HLA genes has proved to
be challenging with mapping bias impeding the accuracy of
genotype calls from short reads (Brandt et al., 2015). To
address this challenge, hla-mapper (Castelli et al., 2018) [v.2.3,
database v002.1, default parameters plus the flags –noclean and –
multiple_hits_MQ0; bwa v.0.7.17 (Li and Durbin, 2010) and
SAMtools v.1.8 (Li et al., 2009)] was used to map the trimmed
reads to the respective HLA class I genes of the human reference
genome build hg19. Per-sample variants from the respective
BAM files of HLA-A, -B, and -C were called using Genome
Analysis Toolkit (GATK) v.4.1.3.0 (Poplin et al., 2017) in GVCF
mode with default parameters considering chromosome 6 of
hg19 as reference. Per-sample GVCFs were consolidated using
GATK GenomicsDBImport and jointly genotyped using GATK
GenotypeGVCFs producing a set of jointly called SNPs and
Indels. Variants were annotated using bcftools (SAMtools) with
the pattern ‘CHR:POS:REF:ALT.’
Variants were converted to PLINK BED files using PLINK
v.1.9 retaining only biallelic sites. Biallelic variants were filtered
on the basis of variant call rate (removing variants missing in > 1
sample), minor allele frequency (removing variants with < 4
minor variant allele count), and deviations from HWE in tolerant
controls (removing variants with HWE exact test p < 0.001).
Statistical Analysis
Statistical analyses of the HTS typing results in the discovery
subset were performed using the R language for statistical
computing v.3.5.3 (R Development Core Team,, 2019).
Individual alleles at both three- and two-field resolution
were tested for association with metamizole-induced
neutropenia/agranulocytosis in a two-sided allelic Fisher’s exact
test. Only alleles with at least four observations were included
in the association analyses. Given the exploratory nature of this
discovery analysis, unadjusted p-values were reported and alleles
with p < 0.05 were selected as candidate alleles.
Candidate alleles were subsequently tested in the full Swiss
and in the Spanish and German EuDAC cohorts to assess
replication of these candidate associations. Statistical analyses
were performed as described above but only at two-field
resolution available from HLA imputation using a two-sided
allelic Fisher’s exact test and using the R language for statistical
computing v.3.6.1 (R Development Core Team,, 2019). In the
Swiss cohort, candidate alleles were investigated in the full cohort,
as well as with agranulocytosis cases only (ANC < 0.5 × 109/L;
n = 30). Association results were visualized using the R package
forestplot (Gordon and Lumley, 2019). For replication analyses,
the significance threshold was adjusted to the number of
investigated candidate genes, i.e., p < 0.01 was considered
statistically significant, corresponding to a Bonferroni correction
for 5 independent tests.
TABLE 1 | Patient characteristics of the three independent cohorts.
Cohort Swiss EUDAC EUDAC
NGS discovery German Spanish
Cases Controls Cases Controls Cases Controls
N = 31(45) N = 38‡(191) N = 12 N = 92 N = 29 N = 145
ANC < 500/µL [%] 25[87] NA 12 NA 29 NA
Gender, male [%] 13[42] 17[45] 4[33] NA 6[21] NA
Age, years [%]
<25 7[23] 1[3] 2[16.6] NA 3[10.3] NA
25-44 11[35] 6[16] 6[50] NA 6[21] NA
45-64 10[32] 15[39] 2[16.6] NA 12[41.4] NA
65-74 3[10] 9[24] 2[16.6] NA 5[17] NA
>74 – 7[18] – NA 3[10.3] NA
BMI, median [range] 24 28 NA NA NA NA
[19-47] [16-39]
Latency time*a/treatment durationb, days 17 25 33.5 NA 11.5 NA
[1-204] [1-5297] [4-9855] [1-235]
The HTS discovery subset is shown for the Swiss cohort. aCases, bcontrols. *Latency missing for 3 agranulocytosis cases and 1 neutropenia case. ‡Metamizole-tolerant
controls. NA, not available or not applicable.
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Allelic associations of the filtered biallelic variants identified
in the discovery subset as described in Section “Investigation
of individual variants in classical HLA class I genes from HTS
data in the discovery subset” were tested in PLINK v.1.9 using
Fisher’s exact test. Finally, a discovery meta-analysis of all alleles
was conducted for HLA-A, -B, -C, -DRB1, -DQA1, and -DQB1
including two-field and one-field association results from a two-
sided allelic Fisher’s exact test for the three independent cohorts
(71 agranulocytosis cases and 428 controls). The meta-analysis
was performed using a sample-size-weighted fixed effect scheme
with METAL (Willer et al., 2010). The analysis was based on
p-values, taking both sample size and direction of effect relative
to the effect allele into account, and testing for heterogeneity
of effects between the cohorts. For this discovery meta-analysis,
p < 1 × 10−3 was considered statistically significant. Given the
linkage between HLA genes and particularly among class I and
class II genes, this threshold was selected using the maximum
number of alleles tested in any cohort for the most diverse class
I and II genes, respectively, HLA-B (29 alleles in the Spanish
cohort) and HLA-DRB1 (20 alleles in the Spanish cohort) as an
estimate for the number of independent tests. In each cohort,
only alleles with at least four observations were included in the
initial meta-analysis. For two alleles with the lowest meta-analysis
p-values, for which the initial meta-analysis did not include all
three cohorts due to this frequency cutoff, the meta-analysis was
repeated including data from all three cohorts.
RESULTS
Participants
Of the 96 cases of metamizole-induced agranulocytosis recruited,
ten were excluded as follows: eight cases from the Swiss cohort
(two as being ethnic outliers, two due to ongoing infectious
diseases, four due to immunosuppressive therapy with cytotoxic
drugs) and two cases from the Spanish cohort (suggested ethnic
outliers). Out of the total 443 controls available, fifteen were
excluded as follows: nine from the Swiss cohort (one was
recruited twice as determined by IBD analysis, seven ethnic
outliers and one with low sample call rate), two from the
Spanish cohort (due to cryptic relatedness) and four from the
German cohort (three ethnic outliers and one due to cryptic
relatedness). As determined by the MDS analysis, the proportion
of participants of European ancestry among the total number
recruited for the MIA-CH cohort was thus 96.5%, of which
75.5, 74, and 74% in the case, tolerant control and unexposed
control groups, respectively, reported “Swiss” as their ethnicity.
Characteristics of patients and control subjects are summarized
in Tables 1, 2. The discovery subset included 25 out of 30 (full
Swiss cohort of MIA cases with agranulocytosis, ANC < 500/µL)
and 6 out of 15 cases of neutropenia (ANC < 1500/µL), while all
cases of the German and Spanish cohorts had agranulocytosis.
Sequencing and HTS-Based Typing of
the Discovery Subset
The current HTS method resulted in a mean depth of coverage
in exon 2 of >250x in seven out of eight target genes for all
FIGURE 1 | Mean depth of coverage in exon 2 as reported by HLA-HD of the
eight sequenced genes of interest. Note that two cases were sequenced as
part of preliminary experiments for protocol optimization and are thus not
included in this figure. Additionally, samples that were sequenced but
excluded for analysis are also excluded in this figure.
samples (Figure 1). A considerably higher variation in depth of
coverage between samples was observed in HLA-DRB1, with a
mean depth as low as 24x (Figure 1). Two cases sequenced as
part of preliminary method optimization with a different pooling
protocol were not included in these summary statistics. Mean
depth of coverage in exon 2 of HLA-DRB1 was dependent on
the allele length with lower depth observed for longer alleles
(Supplementary Figure S1). In particular, alleles of the DR53
haplotype, which is characterized by the presence of HLA-DRB4,
and to a lesser extent those of the DR52 haplotype, characterized
by the presence of HLA-DRB3, showed lower depth of coverage
(Supplementary Figure S1). In addition to the genes of interest,
additional HLA loci were amplified in some samples, specifically
the two HLA-A-related pseudogenes HLA-H and HLA-Y, the
HLA-DRB1-related genes HLA-DRB3, -DRB4, and -DRB5, and
pseudogenes HLA-DRB2, -DRB6, and –DRB7 (Supplementary
Figure S2). The presence of HLA-Y, of which only HLA-Y∗02:01
was typed, appeared to be linked to specific HLA-A alleles
(Supplementary Table S4). Five out of eight genes of interest
displayed balanced allele ratios > 0.7 in every sample; whereas
HLA-DQB1 and HLA-DRB1 showed a wider range of observed
allele ratios (Supplementary Figure S3).
In most instances, HLA typing results were accepted as
reported by HLA-HD. Details of discordant typing results that
were investigated in more detail during quality control are shown
in Supplementary Table S5. In summary, 547 of 552 results
were accepted from HLA-HD, of which 477 were identical at
three-field resolution to the result from NGSengine (total of
483 comparisons, excluding HLA-DRB1), and three results were
accepted from NGSengine. In addition, quality control identified
allelic dropout of HLA-DRB1∗07 in two samples, which was
confirmed in both instances using PCR SSP-based HLA typing
by the Transplantation Immunology Laboratory of the Center
for Laboratory Medicine (Inselspital Bern University Hospital).
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FIGURE 2 | Candidate alleles with evidence for association with MIA/MIN (p < 0.05) in the discovery subset at three-field resolution. Odds ratios (OR), 95%
confidence intervals, and unadjusted p-values are shown.
No deviation from HWE was detected for any of the eight
genes of interest.
Association Analyses and Identification
of Candidate Alleles in the Discovery
Subset
Association analysis of individual HLA alleles obtained with
HTS typing in the discovery subset identified eight candidates
for suggestive association with MIN/MIA in five different genes
(Figure 2 and Supplementary Table S6). The same alleles were
identified at three-field (Figure 2) and at two-field resolution
(Supplementary Figure S4). In total, 73 (three-field) and 75
(two-field) alleles were tested. Allele frequencies of all alleles
at three-field resolution in cases and tolerant controls of the
discovery subset are summarized in Supplementary Table S6.
Replication of Candidate Associations
Using HLA Imputation
Accuracy of HLA imputation from genome-wide SNP array data
in the discovery subset was >94% for four out of five imputed
genes (Table 3). Moreover, the identified candidate alleles were
imputed with high sensitivity and specificity in the discovery
subset (Table 4).
Overall, candidate alleles showed a similar trend in the full
Swiss cohort as in the discovery subset, albeit with a smaller effect
size (Figure 3). However, none of the candidate alleles showed
p < 0.01 in the full cohort, whereas a single allele (HLA–C∗04:01)
did so when restricting the analysis to cases with MIA only. This
allele, which was overrepresented in the control group, showed
a stronger association with respect to MIA in the full cohort
(Figure 4). HLA–C∗04:01 was strongly linked to HLA-B∗35:01
with 31 out of 32 carriers of the less common HLA-B∗35:01 allele
also carrying HLA-C∗04:01.
When expanding the analyses to the EuDAC cohorts,
the general trend of the effect of these candidate alleles
TABLE 2 | Patient characteristics of the full Swiss cohort.
Full Swiss cohort
Cases Tolerant Controls Unexposed Controls
N = 45 N = 38 N = 153
ANC < 500/µL 30 NA NA
Gender, male [%] 23[51] 17[45] 72[47]
Age, years [%]
<25 10[22] 1[2.5] 27[17.5]
25-44 14[31] 6[16] 73[48]
45-64 12[27] 15[39.5] 53[34.5]
65-74 7[15.5] 9[24] –
>74 2[4.5] 7[18] –
BMI, median [range] 24[19-47] 28[16-39] 23[18-40]
Latency time*a /
treatment durationb,
days
15[1-204] 25 [5197] NA
aCases, bmetamizole-tolerant controls. *Latency missing for 3 agranulocytosis
cases and 1 neutropenia case. NA, not applicable.
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TABLE 3 | Accuracy of HLA imputation of the five genes where a candidate allele
was identified by HTS in the discovery cohort.
Gene Imputation accuracy
HLA-B 96.4% (133/138)
HLA-C 94.9% (131/138)
HLA-DQA1 97.1% (134/138)
HLA-DQB1 98.6% (136/138)
HLA-DRB1 88.4% (122/138)
Accuracies were determined by comparing the typing results of the discovery
subset, i.e., the samples for which a typing result by HTS was available, to those
obtained by imputation. Number in brackets indicate the number of correctly
imputed alleles and the total number of alleles imputed for each gene.
TABLE 4 | Sensitivity and specificity of HLA imputation for the eight candidate
alleles identified by HTS in the discovery subset compared to HLA typing results of
the HTS method.
Allele Sensitivity Specificity
B*35:01 9/11 (82%) 127/127 (100%)
C*04:01 13/13 (100%) 125/125 (100%)
C*07:04 4/4 (100%) 134/134 (100%)
DQA1*01:02 24/24 (100%) 114/114 (100%)
DQB1*05:01 18/18 (100%) 120/120 (100%)
DQB1*06:04 7/7 (100%) 131/131 (100%)
DRB1*04:01 11/11 (100%) 127/127 (100%)
DRB1*13:02 8/8 (100%) 130/130 (100%)
on MIA was not consistent in all three independent
cohorts (Figure 5). The two most promising, linked
candidate alleles HLA-B∗35:01 and –C∗04:01 showed a
similarly protective trend in the Swiss and German cohorts
including only cases of agranulocytosis, but not in the
Spanish cohort (Figure 4). No global difference of genetic
variation in the HLA region from genome-wide SNP
array data was observed in Spanish versus German and
Swiss controls based on MDS analysis of HLA region SNPs
(Supplementary Figure 5).
Associations of Individual Sequence
Variants in Full-Length Genes
In total, 13 out of 725 tested individual variants obtained
by HTS in the three full-length classical HLA class I
genes were identified as candidates for an association with
MIA/MIN (p < 0.05) (Table 5). Over 50% of carriers of
the alternate allele for 12 out of 13 candidate variants
also carried the candidate allele HLA-C∗04:01 and 100%
of carriers of eight of these variants also carried HLA-
C∗04:01. The remaining candidate variant was carried together
with the candidate allele HLA-C∗07:04 in all carriers of the
alternate allele.
Discovery Meta-Analysis of Imputed HLA
Alleles Across Cohorts
In the meta-analysis of all two-field and one-field resolution
imputed HLA typing across all three cohorts, no alleles were
significantly associated with MIA with a p-value of ≤1 × 10−3
(Supplementary Table S7). In the analysis of alleles at two-field
resolution, the top allele with the smallest p-value was HLA-
A∗68:02 (p = 3 × 10−3). This result was derived only from
the Spanish cohort as this allele had less than four observations
in the other two cohorts. Further exploration of the data for
this allele revealed that HLA-A∗68:02 was not observed in any
of the German or Swiss cases, and a meta-analysis including
the data from these two cohorts yielded a weaker association
result (p = 0.08, Supplementary Table S7). In the analysis
of candidate alleles with one-field resolution, the allele with
FIGURE 3 | Allele frequencies of the two linked candidate alleles, HLA-B∗35:01 and –C∗04:01, that showed a stronger association in the full cohort when restricting
the analysis to agranulocytosis cases only, in all analyzed cohorts and subsets thereof.
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FIGURE 4 | Associations of candidate alleles from the discovery subset at two-field resolution in the full Swiss cohort and in an analysis including only cases with
MIA. HLA typing results obtained by HTS were used if available, else typing results obtained by HLA imputation were used. Alleles in strong linkage disequilibrium are
highlighted in one contiguous gray block. P-values < 0.01 in the full cohort are highlighted with an asterisk.
the smallest p-value was HLA-A∗31 (p = 4.5 × 10−3). This
result did not consider the German cohort where this allele
was not observed in any of the cases and only in two controls.
Also for this allele, inclusion of all three cohorts resulted in
an overall weaker association (p = 0.01, Supplementary Table
S7). When considering these results based on all data from all
three cohorts, the candidate allele HLA-C∗04:01 was thus the
top association signal (p = 0.0059) also in the meta-analysis
(Supplementary Table S7).
DISCUSSION
In this study, we investigated the association between
genetic variation in HLA genes and metamizole-induced
agranulocytosis/neutropenia (MIA/MIN). To our knowledge,
this is the first pharmacogenetic association analysis of
full-length HLA genes using an HTS approach based
on non-commercial primers and utilizing freely available
software tools. This exploratory analysis in a Swiss discovery
subset identified eight candidate alleles in five different
classical class I and II genes to be potentially associated with
MIA/MIN. Candidate alleles were further investigated in an
extended Swiss cohort as well as two independent European
replication cohorts. However, none of these alleles were
consistently associated in all three cohorts and no significant
associations of other alleles were identified in a discovery
meta-analysis of all cohorts, thus challenging the hypothesis
of an HLA-restricted T cell-mediated mechanism behind
metamizole-induced agranulocytosis.
Metamizole-Induced Agranulocytosis
and HLA Gene Variation
The possibility of certain HLA alleles conferring an increased
susceptibility to MIA, which could put certain populations at a
greater risk, has previously been suggested (Vlahov et al., 1996;
Shah, 2018). However, in the current study, no major HLA
risk allele with a strongly increased frequency among patients
with MIA or MIN was detected, thus making a T cell-mediated
immune mechanism restricted by a specific HLA allele unlikely.
Interestingly, previous studies investigating agranulocytosis
related to other drugs found strong associations with HLA risk
alleles (Yunis et al., 1995; Mallal et al., 2002, 2008; Illing et al.,
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FIGURE 5 | Associations of candidate alleles from the discovery subset at two-field resolution in the three independent cohorts, where cases are restricted to those
meeting the criterion for agranulocytosis. HLA typing results obtained by HTS were used if available, else typing results obtained by HLA imputation were used.
Alleles in strong linkage disequilibrium are highlighted in one contiguous gray block. All p-values < 0.01 are highlighted with an asterisk.
TABLE 5 | Results from Fisher’s exact test for association of individual variants in the classical class I genes HLA-A, -B, and –C obtained by variant calling
of the HTS data.
CHR Position Ref Alt Cases Tolerants P OR Gene Exon/Intron Comment
6 31237779 C T 1 (2%) 12 (16%) 0.0063 0.087 HLA-C Exon 5 Co-occured with
C*04:01:01
6 31238027 C A 1 (2%) 12 (16%) 0.0063 0.087 HLA-C Exon 4
6 31238267 C T 1 (2%) 12 (16%) 0.0063 0.087 HLA-C Intron 3
6 31238538 G C 1 (2%) 12 (16%) 0.0063 0.087 HLA-C Intron 3
6 31239082 G C 1 (2%) 12 (16%) 0.0063 0.087 HLA-C Exon 3
6 31239501 G T 1 (2%) 12 (16%) 0.0063 0.087 HLA-C Exon 2
6 31239607 G A 1 (2%) 12 (16%) 0.0063 0.087 HLA-C Exon 2
6 31239742 G C 1 (2%) 12 (16%) 0.0063 0.087 HLA-C Intron 1
6 31239652 G A 3 (5%) 15 (20%) 0.011 0.21 HLA-C Intron 1
6 31239660 G T 3 (5%) 15 (20%) 0.011 0.21 HLA-C Intron 1
6 31237987 C T 2 (3%) 13 (17%) 0.012 0.16 HLA-C Exon 4
6 31239057 C T 5 (8%) 18 (24%) 0.020 0.28 HLA-C Exon 3
6 31238928 TCA T 4 (6%) 0 (0%) 0.039 NA HLA-C Exon 3 Co-occured with
C*07:04:01
Only variants with p < 0.05 are shown and sorted according to p-value. Number of alleles and allele frequency (%) of the alternate allele (Alt) of cases and tolerant controls
are indicated in the columns “Cases” and “Tolerants” respectively. Blocks of variants which are present in the same samples are highlighted in one block of the same
shade of gray. If a shown variant co-occurred with a candidate HLA allele in the discovery subset, i.e., 100% of Alt allele carriers also carried the respective candidate
allele, it is indicated in the column “Comment.” Genomic positions are based on hg19.
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2012; Chen et al., 2015; Hallberg et al., 2016; Saito et al., 2016;
He et al., 2017; Thao et al., 2018; Wadelius et al., 2018), some of
which have been replicated in independent cohorts.
Our findings for MIA do not align with findings for other
agranulocytosis-inducing drugs, raising the question whether the
mechanism of inducing agranulocytosis differs between causal
drugs. Indeed, our findings are consistent with recent functional
studies indicating a direct toxic effect of the main metabolite of
metamizole in the presence of hemin on granulocyte precursors
(Rudin et al., 2019a,b). Moreover, a recent in vitro investigation
of patient-derived peripheral blood cells did not detect any
activation of the adaptive immune system by either metamizole
or its main metabolite (Dina Manuel, 2019). To our knowledge,
only one earlier study investigated HLA variation in the context
of metamizole-induced agranulocytosis (Vlahov et al., 1996),
reporting some associated alleles. However, this study included
only five cases of MIA, and the reported alleles did not show the
same effect in the cohorts analyzed here, which may be explained
by the very limited sample size of the previous investigation.
Taken together, these results thus do not support an HLA-
restricted T cell-mediated mechanism of MIA.
Of note, the candidate allele HLA-C∗04:01:01 with the
strongest evidence for association showed a putative protective
effect, i.e., it was observed at very low frequency or was absent
in MIA cases. Interestingly, a similar trend was observed for
this candidate allele and the linked allele HLA-B∗35:01 in the
German, but only to a much weaker extent in the Spanish cohort.
While no global difference was observed between Spanish,
German and Swiss individuals by MDS analysis of SNPs in
the HLA region, we cannot exclude that individual alleles may
differ in their frequency between these populations, resulting in
differences in the observed associations with MIA as reported
for other idiosyncratic ADRs (Lucena et al., 2011). Nevertheless,
given the exploratory nature of our analyses in the discovery
subset, the identified candidates are expected to include false
positive results. Further validation in additional independent
study populations would thus be required to assess whether HLA-
C∗04:01, which also yielded the top association signal in the
meta-analysis of all alleles in all cohorts, or any of the other
putative candidates confer true associations. However, even if
such a protective effect of HLA-C∗04:01 were indeed present,
its underlying mechanisms would differ from a T cell mediated
mechanism mediated by a specific HLA allele. Importantly, an
association detected in classical HLA genes may also result from
a mechanism mediated by other genes or regulatory variants
in linkage disequilibrium (LD) with HLA alleles as it is often
challenging to differentiate the effect of classical HLA genes and
other non-HLA genes or regulatory variants within this region
(Shiina et al., 2009; McCormack et al., 2011; Alfirevic et al., 2012;
Hosomichi et al., 2013).
As MIA is a rare occurrence, identifying a large number of
cases for genetic association studies is challenging. Nevertheless,
due to the large effect sizes reported for HLA associations with
other idiosyncratic ADRs, our analyses in the Swiss discovery
subset were sufficiently powered to detect associations of similar
magnitude. Specifically, several such previous studies reported
odds ratios (ORs) > 50 (Mallal et al., 2002; Hung et al., 2005;
Daly et al., 2009) and others with somewhat weaker effect sizes
still reported ORs in the range of 7–15 (McCormack et al.,
2011; Wadelius et al., 2018). Given the sample size of the
discovery subset, our study had sufficient power (80%) to detect
associations of rarer (OR ≥ 8.5 for allele frequencies of ≥2%)
and more common alleles with clinically relevant effect sizes [OR
of ≥5.0 for allele frequency of ≥5% and OR of ≥3.7 for allele
frequency of ≥10%; calculated using G∗Power v3.1 (Faul et al.,
2007; Erdfelder et al., 2009)]. These minimum detectable ORs are
thus lower than most previously reported associations of HLA
risk alleles mentioned above.
Another challenging aspect to be noted is the ascertainment
of metamizole as the causative agent for agranulocytosis and
the lack of data on neutrophil counts prior to metamizole
administration. Multiple medications that are commonly
used concurrently with metamizole such as beta-lactam
antibiotics, have also been associated with lowered neutrophil
counts. However, restricting analyses to patients without
such concomitant medications would result in very limited
sample sizes and an associated loss in statistical power. Finally,
while HLA alleles in the discovery subset were determined
at higher resolution using HTS, the typing resolution in the
replication cohorts based on HLA imputation was limited.
While concordance of HLA imputation at two-field resolution
with HTS-based typing was generally high, particularly for
one of the candidate alleles (HLA-B∗35:01), a slightly reduced
sensitivity was observed. Importantly, HLA imputation accuracy
is limited by the resolution of the reference data available, which
is currently primarily based on traditional HLA typing methods.
HTS-Based HLA Sequencing for
Pharmacogenetic Association Studies
With the present method, we obtained three-field resolution HLA
typing results, achieving higher resolution and less ambiguity
compared to traditional HLA typing methods based on core
exons alone or with HLA imputation. As a result, using HTS-
based direct analysis of the HLA region may have benefits for
future genetic association studies. In this context, our results
demonstrate the feasibility of HTS-based HLA analyses in
pharmacogenetic studies using non-commercial methods and
data analysis tools.
The development of HTS-based HLA typing approaches has
been met with great enthusiasm (Carapito et al., 2016; Kishore
and Petrek, 2018) but currently faces certain limitations. Similar
to other HTS-methods, our analysis included full-length genes,
enabling, in principle, typing at four-field resolution. To date,
however, this resolution was limited to three fields due to the
limited characterization of intronic and UTR regions in the HLA
reference database (Kawaguchi et al., 2017). A more complete
dictionary of full-length reference sequences for HLA alleles
is imperative to support full four-field resolution typing and
maximize the potential of HTS-based HLA analysis.
In contrast to another recent pharmacogenetic association
study using HTS-based HLA typing (Nakatani et al., 2019),
our analyses not only included HLA typing, but also assessed
sequence variation at the level of SNVs in full-length class
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I genes. Such analyses at the level of individual SNVs may
complement traditional haplotype-level allele typing approaches
in association studies by enabling the detection of associations for
SNVs contained on multiple HLA alleles, for which analyses at
the allele-level may be underpowered. Similarly, it may uncover
causal variants underlying known haplotype-level associations
with ADRs or diseases by providing effect sizes for individual
sequence changes.
We restricted our present analysis of individual HLA SNVs
to class I genes as hla-mapper, the HLA-dedicated mapping
tool, was only available for these genes. Due to the extensive
sequence variation in HLA genes, variant calls in the HLA
region obtained from standard read mapping pipelines have been
reported to show a higher error rate compared to other parts
of the human genome with a reference allele bias (Brandt et al.,
2015). The congruence of our variant calling results with the
results of HLA typing demonstrates the feasibility of achieving
sequence variation data at the level of individual SNVs with the
help of publicly available HLA-specific software. However, such
software is currently scarce and not available for HLA class II
genes, which display a more challenging pattern of variation,
including structural variants encompassing larger gene regions
and pseudogenes with highly similar sequences (Klasberg et al.,
2019). Thus, for a more comprehensive assessment of HLA
variation at the level of SNVs, additional or updated HLA-specific
mapping tools that include class II genes are needed.
The present method differs from other non-commercial HLA
HTS methods (Hosomichi et al., 2013; Ehrenberg et al., 2017)
in that it relies on an enzymatic fragmentation of amplicons
and instead of a tagmentation approach in order to minimize
coverage bias (Lima et al., 2019). This alternative library
preparation approach presented here may thus be applied to
long-range PCR products generated with any available primers to
amplify HLA genes. Furthermore, in contrast to the method used
here, some commercially available HTS-based HLA typing kits
do not amplify exon 1 and parts of intron 1 of most HLA class II
genes, thus leading to ambiguous three-field typing results. This
omission of exon 1 likely reflects the difficulty in amplifying full-
length class II genes as single amplicons with even amplification
efficacy across alleles. In particular, the genomic length of HLA-
DRB1 varies considerably between alleles, primarily due to large
structural variants in intron 1 (Von Salomé et al., 2007). Indeed,
we observed a lower amplification efficiency of longerHLA-DRB1
alleles leading to more pronounced allelic imbalance and some
allelic dropout. Amplification efficiency of some HLA-DRB1
alleles may be further impaired by co-amplification ofHLA-DRB4
or -DRB2. Here, we detected suspected allelic dropout for several
samples using our quality control procedure. Nevertheless, given
the low allele ratios for HLA-DQB1 observed in a few samples,
and it is possible that some additional allelic dropout was not
detected. This allelic imbalance could potentially be reduced by
using higher PCR primer concentrations as previously described
(Hosomichi et al., 2013; Ehrenberg et al., 2017). Alternatively, for
future studies, it may be advantageous to amplify these class II
genes in two separate amplicons (Shiina et al., 2012).
Finally, our study highlights additional inherent difficulties
in identifying primers that amplify all alleles of full-length
HLA genes without amplifying closely related pseudogenes.
Specifically, in addition to co-amplification of HLA-DRB1 related
genes, we also detected co-amplification of the HLA-A related
pseudogene HLA-Y (Kawaguchi et al., 2017). Of note, this
pseudogene is not included in any of the human reference
genome sequences (primary assembly or alternate haplotype
thereof), making it difficult to account for during primer design.
Given that such co-amplification of pseudogene sequences may
not be fully avoided for HLA genes, it is thus crucial that
their presence be considered at the data analysis stage. For
example, HLA-HD detected reads originating from HLA-Y while
the version of NGSengine used in the presented analyses did
not. Given these numerous challenges associated with PCR
amplification of full-length HLA genes, alternative PCR-free
approaches for isolating genomic target regions for subsequent
HTS, such as the use of CRISPR/Cas9 (Nachmanson et al.,
2018), may prove advantageous for future analysis of this
genomic region.
CONCLUSION
In this study, we did not find any consistent associations between
HLA alleles and MIA across different cohorts by investigating
variation in HLA genes in detail. In particular, no strong
enrichment of distinct HLA alleles in patients with MIA was
found. Our results, therefore, do not support an HLA-restricted
T cell-mediated immune mechanism of MIA. Nevertheless, our
study presents the feasibility of HTS-based analysis of HLA genes
in the context of a pharmacogenetic association study, without
the need to rely on costly commercial solutions, and highlights
the need for further development of dedicated bioinformatics
tools for HTS-based HLA data analysis.
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Carrington, M., et al. (2011). HLA-A∗3101 and carbamazepine-induced
hypersensitivity reactions in Europeans. N. Engl. J. Med. 364, 1134–1143. doi:
10.1056/NEJMoa1013297
Miljkovic, M., Dragojevic-Simic, V., Rancic, N., Simic, R., Pekez-Pavlisko, T.,
Kovacevic, A., et al. (2018). Metamizole utilization and expenditure during 6-
year period: Serbia vs. Croatia. Front. Public Heal. 6:213. doi: 10.3389/fpubh.
2018.00213
Nachmanson, D., Lian, S., Schmidt, E. K., Hipp, M. J., Baker, K. T., Zhang, Y., et al.
(2018). Targeted genome fragmentation with CRISPR/Cas9 enables fast and
efficient enrichment of small genomic regions and ultra-accurate sequencing
with low DNA input (CRISPR-DS). Genome Res. 28, 1589–1599. doi: 10.1101/
gr.235291.118
Nakatani, K., Ueta, M., Khor, S. S., Hitomi, Y., Okudaira, Y., Masuya, A., et al.
(2019). Identification of HLA-A∗02:06:01 as the primary disease susceptibility
HLA allele in cold medicine-related Stevens-Johnson syndrome with severe
ocular complications by high-resolution NGS-based HLA typing. Sci. Rep.
9:16240. doi: 10.1038/s41598-019-52619-2
Nariai, N., Kojima, K., Saito, S., Mimori, T., Sato, Y., Kawai, Y., et al.
(2015). HLA-VBSeq: accurate HLA typing at full resolution from whole-
genome sequencing data. BMC Genomics. 16:S7. doi: 10.1186/1471-2164-
16-S2-S7
Poplin, R., Ruano-Rubio, V., DePristo, M. A., Fennell, T. J., Carneiro, M. O.,
Auwera, G. A., et al. (2017). Scaling accurate genetic variant discovery to tens
of thousands of samples. bioRxiv[Preprint] doi: 10.1101/201178
Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira, M. A. R., Bender, D.,
et al. (2007). PLINK: a tool set for whole-genome association and population-
based linkage analyses. Am. J. Hum. Genet. 81, 559–575. doi: 10.1086/51
9795
R Development Core Team, (2019). R: A Language and Environment for Statistical
Computing. Vienna: R Development Core Team.
Raymond, M., and Rousset, F. (1995). GENEPOP (Version 1.2): population
genetics software for exact tests and ecumenicism. J. Hered. 86, 248–249. doi:
10.1093/oxfordjournals.jhered.a111573
Robinson, J., Halliwell, J. A., Hayhurst, J. D., Flicek, P., Parham, P.,
and Marsh, S. G. E. (2015). The IPD and IMGT/HLA database: allele
variant databases. Nucleic Acids Res. 43, D423–D431. doi: 10.1093/nar/gku
1161
Rousset, F. (2008). GENEPOP’007: a complete re-implementation of the
GENEPOP software for Windows and Linux. Mol. Ecol. Resour. 8, 103–106.
doi: 10.1111/j.1471-8286.2007.01931.x
Rudin, D., Lanzilotto, A., Bachmann, F., Housecroft, C. E., Constable, E. C., Drewe,
J., et al. (2019a). Non-immunological toxicological mechanisms of metamizole-
associated neutropenia in HL60 cells. Biochem. Pharmacol. 163, 345–356. doi:
10.1016/J.BCP.2019.01.011
Rudin, D., Roos, N. J., Duthaler, U., and Krähenbühl, S. (2019b).
Toxicity of metamizole on differentiating HL60 cells and human
neutrophil granulocytes. Toxicology 426:152254. doi: 10.1016/j.tox.2019.15
2254
Rudin, D., Spoendlin, J., Cismaru, A. L., Liakoni, E., Bonadies, N., Amstutz, U.,
et al. (2019c). Metamizole-associated neutropenia: comparison of patients with
neutropenia and metamizole-tolerant patients. Eur. J. Intern. Med. 68, 36–43.
doi: 10.1016/j.ejim.2019.07.029
Saito, T., Ikeda, M., Mushiroda, T., Ozeki, T., Kondo, K., Shimasaki,
A., et al. (2016). Pharmacogenomic study of clozapine-induced
agranulocytosis/granulocytopenia in a Japanese population. Biol. Psychiatry.
80, 636–642. doi: 10.1016/j.biopsych.2015.12.006
Sánchez, S., De la Lastra, C. A., Ortiz, P., Motilva, V., and Martín, M. J. (2002).
Gastrointestinal tolerability of metamizol, acetaminophen, and diclofenac in
subchronic treatment in rats. Dig. Dis. Sci. 47, 2791–2798. doi: 10.1023/A:
1021077810548
Shah, R. R. (2018). Metamizole (dipyrone)-induced agranulocytosis: does the risk
vary according to ethnicity? J. Clin. Pharm. Ther. 44, 129–133. doi: 10.1111/jcpt.
12768
Shiina, T., Hosomichi, K., Inoko, H., and Kulski, J. K. (2009). The HLA genomic
loci map: expression, interaction, diversity and disease. J. Hum. Genet. 54,
15–39. doi: 10.1038/jhg.2008.5
Shiina, T., Suzuki, S., Ozaki, Y., Taira, H., Kikkawa, E., Shigenari, A., et al. (2012).
Super high resolution for single molecule-sequence-based typing of classical
HLA loci at the 8-digit level using next generation sequencers. Tissue Antigens
80, 305–316. doi: 10.1111/j.1399-0039.2012.01941.x
Stammschulte, T., Ludwig, W. D., Mühlbauer, B., Bronder, E., and Gundert-Remy,
U. (2015). Metamizole (dipyrone)-associated agranulocytosis. an analysis of
German spontaneous reports 1990-2012. Eur. J. Clin. Pharmacol. 71, 1129–
1138. doi: 10.1007/s00228-015-1895-y
Thao, M. P., Tuan, P. V. A., Linh, L. G. H., Van Hoang, L., Hen, P. H., Hoa,
L. T., et al. (2018). Association of HLA-B – 38:02 with antithyroid drug-induced
agranulocytosis in kinh vietnamese patients. Int. J. Endocrinol. 2018:7965346.
doi: 10.1155/2018/7965346
Turner, S., Armstrong, L. L., Bradford, Y., Carlsony, C. S., Crawford, D. C.,
Crenshaw, A. T., et al. (2011). Quality control procedures for genome-wide
association studies. Curr. Protoc. Hum. Genet. Chapter 1:Unit1.19. doi: 10.1002/
0471142905.hg0119s68
Uetrecht, J. P. (1996). Reactive metabolites and agranulocytosis. Eur. J. Haematol.
Suppl. 57, 83–88. doi: 10.1111/j.1600-0609.1996.tb01651.x
Van der Klauw, M. M., Goudsmit, R., Halie, M. R., Van’t Veer, M. B., Herings,
R. M. C., Wilson, J. H. P., et al. (1999). A population-based case-cohort study of
drug-associated agranulocytosis. Arch. Intern. Med. 159, 369–374. doi: 10.1001/
archinte.159.4.369
Vlahov, V., Bacracheva, N., Tontcheva, D., Naumova, E., Mavrudieva, M., Ilieva,
P., et al. (1996). Genetic factors and risk of agranulocytosis from metamizol.
Pharmacogenetics 6, 67–72. doi: 10.1097/00008571-199602000-00005
Von Salomé, J., Gyllensten, U., and Bergström, T. F. (2007). Full-length
sequence analysis of the HLA-DRB1 locus suggests a recent origin of alleles.
Immunogenetics 59, 261–271. doi: 10.1007/s00251-007-0196-8
Wadelius, M., Eriksson, N., Kreutz, R., Bondon-Guitton, E., Ibañez, L., Carvajal,
A., et al. (2018). Sulfasalazine-induced agranulocytosis is associated with the
human leukocyte antigen locus. Clin. Pharmacol. Ther. 103, 843–853. doi: 10.
1002/cpt.805
Warren, R. L., Choe, G., Freeman, D. J., Castellarin, M., Munro, S., Moore, R., et al.
(2012). Derivation of HLA types from shotgun sequence datasets. GenomeMed.
4:95. doi: 10.1186/gm396
Willer, C. J., Li, Y., and Abecasis, G. R. (2010). METAL: fast and efficient meta-
analysis of genomewide association scans. Bioinformatics 26, 2190–2191. doi:
10.1093/bioinformatics/btq340
Yunis, J. J., Corzo, D., Salazar, M., Lieberman, J. A., Howard, A., and Yunis,
E. J. (1995). HLA associations in clozapine-induced agranulocytosis. Blood 86,
1177–1183. doi: 10.1182/blood.v86.3.1177.bloodjournal8631177
Zheng, X., Shen, J., Cox, C., Wakefield, J. C., Ehm, M. G., Nelson, M. R.,
et al. (2014). HIBAG—HLA genotype imputation with attribute bagging.
Pharmacogenomics J. 14, 192–200. doi: 10.1038/tpj.2013.18
Conflict of Interest: The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.
Copyright © 2020 Cismaru, Grimm, Rudin, Ibañez, Liakoni, Bonadies, Kreutz,
Hallberg, Wadelius, EuDAC Collaborators, Haschke, Largiadèr and Amstutz. This
is an open-access article distributed under the terms of the Creative Commons
Attribution License (CC BY). The use, distribution or reproduction in other forums
is permitted, provided the original author(s) and the copyright owner(s) are credited
and that the original publication in this journal is cited, in accordance with accepted
academic practice. No use, distribution or reproduction is permitted which does not
comply with these terms.
Frontiers in Genetics | www.frontiersin.org 15 August 2020 | Volume 11 | Article 951
